Drug name - Caplyta
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9586960 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(6 years from now) | |
| USRE48825 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(6 years from now) | |
| US8648077 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Dec, 2029
(7 years from now) | |
| CN102046175A | INTRA-CELLULAR | Substituted Heterocycle Fused Gamma-Carbolines Solid |
Mar, 2029
(6 years from now) | |
| CN102046175B | INTRA-CELLULAR | A Heterocyclic Ring Fused Gamma-Carbolines Solid |
Mar, 2029
(6 years from now) | |
| EP2262505B1 | INTRA-CELLULAR | Substituted Heterocycle Fused Gamma-Carbolines Solid |
Mar, 2029
(6 years from now) | |
| EP2262505A2 | INTRA-CELLULAR | Substituted Heterocycle Fused Gamma-Carbolines Solid |
Mar, 2029
(6 years from now) | |
| EP2262505A4 | INTRA-CELLULAR | Substituted Heterocycle Fused Gamma-Carbolines Solid |
Mar, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10464938 | INTRA-CELLULAR | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof |
Mar, 2028
(5 years from now) | |
| US9199995 | INTRA-CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Mar, 2029
(6 years from now) | |
| US10117867 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(6 years from now) | |
| US9616061 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(6 years from now) | |
| USRE48839 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Dec, 2029
(7 years from now) | |
| US8598119 | INTRA-CELLULAR | Methods and compositions for sleep disorders and other disorders |
Dec, 2029
(7 years from now) | |
| US10960009 | INTRA-CELLULAR | Methods of treating schizophrenia and depression |
Dec, 2034
(12 years from now) | |
| US11026951 | INTRA-CELLULAR | Methods of treating bipolar disorder |
Dec, 2034
(12 years from now) | |
| US9956227 | INTRA-CELLULAR | Method for the treatment of residual symptoms of schizophrenia |
Dec, 2034
(12 years from now) | |
| US10695345 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(16 years from now) | |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of bipolar depression; treatment of schizophrenia; Treatment of schizophrenia; Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia with improvement in residual symptoms of schizophrenia
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 42MG BASE | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.